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Letters to the
Editor
The Ross operation as an ideal
choice for aortic valve replacement
in patients with congenital disease
To the Editor:
We read with interest the article by Al-
Halees and associates1 concerning the Ross
procedure for congenital aortic valve dis-
ease, and we congratulate them for their
valuable work.
They treated 53 patients with congenital
heart disease aged 3 months to 18 years
(median 9 years). Ten patients were
younger than 2 years of age. The mean
cardiopulmonary bypass time was 109 
36 minutes (52-243 minutes) with a mean
crossclamping time 79.5 minutes (45-164
minutes).
The mean follow-up was 4 years with 3
hospital deaths, all among patients with
subaortic stenosis. One patient needed au-
tograft replacement for endocarditis. A
right ventricular outflow tract gradient ne-
cessitated balloon dilatation in 2 and reop-
eration in 1. All patients but 1 have normal
or near-normal autograft valve function.
The homografts in the pulmonary position
demonstrated gradients in 14 patients; 9
gradients were less than 35 mm Hg and 5
greater than 50 mm Hg. Three of the pa-
tients underwent reoperation.
We have a similar group of 26 patients
(age range 2.5 months-12 years, median
6.9 years, 5  1 year; weight range 4.9-42
kg, median 23.6 kg, 7  10 kg) having the
Ross operation for congenital aortic valve
disease: aortic stenosis in 24 and congenital
insufficiency in 2. Twelve patients had ad-
ditional malformations: subaortic stenosis
in 7, coarctation of the aortic isthmus in 2,
mitral insufficiency in 2, and ventricular
septal defect in 1. Thirteen patients had a
prior operation: aortic valvotomy in 11,
balloon dilatation in 4, coarctation repair in
2, and aortic root replacement by a ho-
mograft in 1.
We used the widest possible pulmonary
homografts in all patients. Concomitant
surgical procedures were performed in 9
patients: 2 mitral valve repairs, 2 resections
of a subaortic membrane, and 5 Konno
repairs for subaortic stenosis (cardiopulmo-
nary bypass time 114-162 minutes, median
137.3 minutes; aortic crossclamping time
97-143 minutes, median 123.1 minutes for
autograft preparation and implantation and
homograft implantation).
There were no hospital deaths but 2
instances of delayed sternal closure and 1
pacemaker implantation. During follow-up
(1-8 years, median 4.1 years), there was 1
late death during reoperation for false aor-
tic aneurysm of the proximal anastomosis 6
months postoperatively. One patients had a
modified Konno procedure for subaortic
stenosis (infundibulotomy with a vertical
incision in the subannular left ventricular
outflow tract and patch repair). Minimal
aortic insufficiency is present in 7 patients,
and 4 patients have asymptomatic gradients
on the homograft (20-35 mm Hg). Al-
Halees and associates did not explain the
conduct and short duration of cardiopulmo-
nary bypass (minimum 52 minutes with 45
minutes of aortic clamping), which are dif-
ferent from most related publications.2,3
One of the differences between their
results and ours is that the hospital mortal-
ity is confined to patients with left ventric-
ular outflow tract obstruction (the total
number with involvement of the outflow
tract is not mentioned), making their surgi-
cal technique for relief of outflow tract
obstruction questionable. Another differ-
ence is the right ventricular outflow tract
gradient in 25% (more than 50 mm Hg in
9%) of their patients despite the use of
immunosuppressive therapy. We think our
result is due to the use of pulmonary ho-
mografts. Despite these differences in re-
sults, both studies confirm that the Ross
operation represents the best choice for
aortic valve replacement in infants and
children.
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Preoperative platelet inhibition and
bleeding after cardiopulmonary
bypass
To the Editor:
Bizzari and associates1 studied clinical
events and potential bleeding complica-
tions in a group of patients who had under-
gone emergency or urgent cardiac surgery
after treatment with tirofiban hydrochlo-
ride. They observed that patients treated
with tirobifan had a smaller decrease in
platelet count during cardiopulmonary by-
pass; other platelet suppressants have sim-
ilar effects.2,3 Preoperative platelet inhibi-
tion will reduce the platelet loss associated
with cardiopulmonary bypass because a
preferential loss of activated platelets is
observed during the period of extracorpo-
real circulation.4,5 The hemostatic function
of the preserved platelets would, however,
be impaired by heparin-induced plasma
changes.6
The study was undertaken because of a
concern that platelet inhibition may exac-
erbate bleeding after cardiopulmonary by-
pass. We among others have demonstrated
that during cardiopulmonary bypass plate-
lets lose the ability to form large stable
aggregates (macroaggregates).6-9 This im-
pairment persists for several hours postop-
eratively.7,8 Macroaggregation is important
for platelet hemostatic function because it
gives strength to a platelet plug and paves
the way for clot retraction. As platelet mac-
roaggregation is virtually abolished during
cardiopulmonary bypass,6-9 we suggest that
additional platelet suppression is unlikely
further to impair hemostasis or increase
bleeding during the immediate postopera-
tive period. Furthermore, after cardiopul-
monary bypass platelets appear resistant to
aspirin,10 an irreversible platelet inhibi-
tor; it is therefore unlikely that even
long-acting platelet suppressants that are
administered preoperatively will signifi-
cantly impair platelets late in the postop-
erative period. This would explain why
patients who received platelet suppres-
sants shortly before undergoing surgery
using cardiopulmonary bypass did not
appear to bleed excessively when com-
pared with those who did not receive
these drugs.1-3
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Transapical aortic cannulation for
acute aortic dissection with diffuse
atherosclerosis
To the Editor:
We read with interest the article by Fukuda
and associates1 and congratulate them on
their good results. We agree that femoral
artery cannulation sometimes must be
abandoned as arterial access for cardiopul-
monary bypass. Recently we operated on
an urgent basis on a 54-year-old man with
type A acute aortic dissection. The femoral
artery could not be used as arterial access
because of tinea inguinalis. We chose the
subclavian artery instead.
We doubt the reliability of transapical
aortic cannulation in median sternotomy.
We suspect that Fukuda and associates1
happened to dodge the drawbacks of using
this procedure by mere luck, because hy-
potension during elevation of the apex, dis-
location of the cannula, incompetence of
the aortic valve, and repair of the insertion
site are usually inevitable. Insufficient
myocardial protection because of the in-
ability to clamp the ascending aorta and to
administer cardioplegic solution remains a
problem to be solved. If Fukuda and asso-
ciates1 have had experience with other
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